Last $75.79 USD
Change Today +0.33 / 0.44%
Volume 532.3K
MDVN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Stuttgart
As of 8:10 PM 07/25/14 All times are local (Market data is delayed by at least 15 minutes).

medivation inc (MDVN) Snapshot

Open
$75.46
Previous Close
$75.46
Day High
$76.37
Day Low
$74.85
52 Week High
02/25/14 - $88.20
52 Week Low
10/22/13 - $48.15
Market Cap
5.8B
Average Volume 10 Days
867.8K
EPS TTM
$-0.40
Shares Outstanding
76.5M
EX-Date
07/27/99
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MEDIVATION INC (MDVN)

medivation inc (MDVN) Related Businessweek News

No Related Businessweek News Found

medivation inc (MDVN) Details

Medivation, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC) patients. The company also conducts various trials of enzalutamide in earlier prostate cancer disease states, including the Phase III PREVAIL trial in patients with mCRPC who have not received chemotherapy; and in patients with breast cancer. It has collaboration agreement with Astellas Pharma, Inc. for the development, manufacture, and commercialization of XTANDI. The company is headquartered in San Francisco, California.

393 Employees
Last Reported Date: 05/8/14

medivation inc (MDVN) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: $750.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $480.4K
Chief Compliance Officer, General Counsel and...
Total Annual Compensation: $400.0K
Compensation as of Fiscal Year 2013.

medivation inc (MDVN) Key Developments

Medivation Announces Change in Executive Management Team

Medivation, Inc. announced Dawn Svoronos (formerly Graham) has been appointed as its chief commercial officer, reporting to David Hung, M.D., founder, chief executive officer and president of Medivation. Ms. Svoronos currently is a member of Medivation's Board of Directors and is a former president of Europe and Canada for Merck & Co. Inc, where she oversaw commercial operations in approximately 30 EU and EU accession countries. Ms. Svoronos will lead Medivation's commercial organization on an interim basis and will participate in the Company's search for a permanent chief commercial officer. Cheryl Cohen, Medivation's former chief commercial officer, has left the company to pursue other opportunities. Ms. Svoronos, who was elected to Medivation's Board of Directors in April 2013, has more than 30 years of pharmaceutical industry experience spanning the U.S., Europe, Asia and Canada.

Medivation, Inc. and Astellas Pharma US, Inc. Announce Results from Phase 3 Prevail Trial of Enzalutamide in Men with Chemotherapy-Naive Metastatic Prostate Cancer Progressing Despite Androgen Deprivation Therapy

Medivation, Inc. and Astellas Pharma US, Inc. announced the results from the Phase 3 PREVAIL trial, an international, randomized, double-blind, placebo-controlled clinical study of enzalutamide. The study evaluated the benefit and safety of enzalutamide in men with metastatic prostate cancer, who had few or no symptoms, that had progressed on luteinizing hormone-releasing hormone (LHRH) therapy or after bilateral orchiectomy. A supplemental New Drug Application (sNDA) based on the PREVAIL results received a priority review designation from the U.S. Food and Drug Administration (FDA). The Prescription Drug User Fee Act (PDUFA) goal date is September 18, 2014. A variation application to amend the European Marketing Authorization Application based on the results of PREVAIL was validated for review by the European Medicines Agency on April 24, 2014. PREVAIL Trial: The Phase 3 PREVAIL trial is a randomized, double-blind, placebo-controlled, multi-national trial that enrolled more than 1,700 patients at sites in the United States, Canada, Europe, Australia, Russia, Israel and Asia including Japan. The trial enrolled patients with chemotherapy-naïve metastatic prostate cancer whose disease progressed on androgen deprivation therapy (i.e., a luteinizing hormone-releasing hormone (LHRH) therapy or after bilateral orchiectomy). The co-primary endpoints of the trial were overall survival and radiographic progression-free survival. The trial was designed to evaluate enzalutamide at a dose of 160 mg taken orally once daily versus placebo. In the PREVAIL trial, men treated with enzalutamide demonstrated a statistically significant delay in cancer progression and reduction in the risk of death compared with placebo. Enzalutamide reduced the risk of radiographic progression or death by 81% (HR=0.19; p < 0.0001), compared with placebo. The rate of radiographic progression-free survival at 12 months of follow up was 65% among patients treated with enzalutamide, as compared with 14% among patients receiving placebo. Enzalutamide reduced the risk of death by 29% (HR=0.71; p < 0.0001), compared with placebo. A total of 626 patients (72%) in the enzalutamide group, as compared with 532 patients (63%) in the placebo group, were alive at the September 16, 2013 data cutoff date. The most common clinically relevant adverse events associated with enzalutamide treatment as compared with placebo-treated patients in the PREVAIL trial included fatigue, hot flush and hypertension; hypertension was observed in 13.4% of enzalutamide versus 4.1% of placebo-treated patients. Grade 3 or higher cardiac adverse events were reported in 2.8% of enzalutamide versus 2.1% of placebo-treated patients. One patient experienced a seizure in each treatment group.

Medivation, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-03-2014 08:00 AM

Medivation, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-03-2014 08:00 AM. Venue: Grand Hyatt, New York, New York, United States. Speakers: David T. Hung, Chief Executive Officer, President and Executive Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDVN:US $75.79 USD +0.33

MDVN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Dendreon Corp $2.14 USD -0.05
Insys Therapeutics Inc $29.16 USD +1.53
InterMune Inc $45.50 USD -0.43
Sanofi India Ltd 2,950 INR -5.00
Seattle Genetics Inc $34.89 USD +0.20
View Industry Companies
 

Industry Analysis

MDVN

Industry Average

Valuation MDVN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 18.4x
Price/Book 70.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 17.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDIVATION INC, please visit www.medivation.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.